{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-005743","form_type":"8-K","ticker":"SIGY","cik":"0001642159","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.525727+00:00","generated_at":"2026-06-27T03:02:58.277955+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sigyn Therapeutics completes animal study for Sigyn Therapy; safe and well-tolerated in 8 subjects","bullets":["Eight porcine subjects received up to six-hour treatments; no serious adverse events reported.","One treatment halted due to clot from procedural deviation; no serious outcome observed.","Company plans to submit IDE to FDA to support initiation of human clinical studies.","In vitro studies validated broad-spectrum removal of endotoxins, cytokines, and viral pathogens.","CEO states milestone advances clinical vision for sepsis treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-005743","json":"https://secwatch.observer/filing/0001493152-22-005743.json","markdown":"https://secwatch.observer/filing/0001493152-22-005743.md","text":"https://secwatch.observer/filing/0001493152-22-005743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642159/000149315222005743/0001493152-22-005743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642159/000149315222005743/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:02:58.277955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}